an optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl or optionally substituted heteroaryl ring, or

R_5 and R_7, taken together any intervening atoms, form an optionally substituted 5- to 7-membered cycloalkyl or optionally substituted 5- to 7-membered heterocycloalkyl; and

R_6 andR_7 are independently chosen from hydrogen, halo, optionally substituted amino, hydroxyl, lower alkoxy, and optionally substituted lower alkyl, or

R_6 and R_7, taken together with any intervening atoms, form an optionally substituted 5- to 7-membered cycloalkyl or optionally substituted 5- to 7-membered heterocycloalkyl, or

R_6 and R_2, taken together with any intervening atoms, form an optionally substituted 5- to 7-membered cycloalkyl or optionally substituted 5- to 7-membered heterocycloalkyl,

provided that when R_1 is 3-chlorophenyl or 3,4-dichlorophenyl and X is $-CH_2-$, $-CF_2-$, $-CH(CH_3)-$ or $-C(CH_3)_2-$ then -L-R_5 is not -COOH, -CHO, $-C(O)NH_2$, $-C(O)NHCH_3$, $-C(O)NHCH_2$-phenyl, -C(O)NH-phenyl, -C(O)-NH(OH), $-C(O)NHSO_2$-phenyl, -C(O)O-t-butyl, $-C(O)OCH_3$, or -C(O)-NH-CH(phenyl)-CH_2CH_2OH.

[0012] Also provided is a pharmaceutical composition comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and at least one pharmaceutically acceptable excipient.

[0012A] Also provided is use of at least one compound as presently disclosed, or a pharmaceutically acceptable salt or prodrug thereof in the manufacture og a medicament for treating a condition or disorder mediated by Kynurenine 3-mono-oxygenase activity in a subject in need of such a treatment.

[0013] Also provided is a method of treating a condition or disorder mediated by Kynurenine 3-mono-oxygenase activity in a subject in need of such a treatment which method comprises administering to the subject a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof described herein.

[0014] Also provided is a method of treating a condition or disorder mediated by Kynurenine 3-mono-oxygenase activity in a subject in need of such a treatment which method comprises administering to the subject a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein.

[0015] Also provided is a packaged pharmaceutical composition comprising at least one pharmaceutical composition described herein and instructions for using the composition to treat a

41. The compound of claim 40, or a pharmaceutically acceptable salt or prodrug thereof, wherein R_5 is chosen from cyano and optionally substituted heteroaryl.

42. The compound of claim 41, or a pharmaceutically acceptable salt or prodrug thereof, wherein R_5 is chosen from 1,2,3,4-tetrazol-5-yl and 4,5-dihydro-1,2,4-oxadiazol-5-one-3-yl.

43. A compound chosen from the compounds listed in any one of Tables 1-5 or a pharmaceutically acceptable salt or prodrug thereof.

44. A pharmaceutical composition comprising at least one compound of any one of claims 1 to 43, or a pharmaceutically acceptable salt or prodrug thereof, and at least one pharmaceutically acceptable excipient.

45. ~~A method of treating a condition or disorder mediated by Kynurenine 3-mono-oxygenase activity in a subject in need of such a treatment which method comprises administering to the subject a therapeutically effective amount~~ Use of at least one compound of any one of claims 1 to 43, or a pharmaceutically acceptable salt or prodrug thereof in the manufacture of a medicament for treating a condition or disorder mediated by Kynurenine 3-mono-oxygenase activity in a subject in need of such a treatment.

46. The ~~method~~use of claim 45 wherein said condition or disorder involves a neurodegenerative pathology.